Phase 2 N=40 Lenalidomide for Patients With Myelofibrosis (MF)
Myelofibrosis
Primary: Number of Patients With Objective Response (Complete and Partial Response + Hematological Improvement) — 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 A Phase II Study of CC-5013 in Myelofibrosis
Myelofibrosis
Primary: Efficacy of CC-5013 in Myelofibrosis — 7; 9; 12; 9 Participants
Phase 2 N=27 A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
Primary Myelofibrosis · Polycythemia Vera · Post-Essential Thrombocythemia Myelofibrosis
Primary: Stage 1 Main Phase: Overall Response Rate (ORR) — 37.5; 14.3; 33.3; 50.0 Percentage of Participants
Phase 3 N=252 Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
Myelofibrosis (MF)
Primary: Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24 (SVR35W24) — 31.50; 63.20 percentage of participants — p=<0.0001
Phase 2 N=48 Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
Essential Thrombocythemia · Polycythemia Vera · Primary Myelofibrosis
Primary: Overall Response Rate — 0.26 Proportion of participants
Phase 2 N=77 CC-4047 in Treating Patients With Myelofibrosis
Chronic Myeloproliferative Disorders · Secondary Myelofibrosis
Primary: Determine the Maximum Tolerated Dose of CC-4047 — 0; 0; 66 percentage of participants with DLT
Phase 3 N=2,233 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.
Myelofibrosis
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 Years — 2153; 830 Participants
Phase 2 N=41 Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Primary Myelofibrosis (PMF) · Post-polycythemia Vera (Post-PV) Myelofibrosis · Postessential Thrombocythemia (Post-ET) Myelofibrosis
Primary: Transfusion Independence Response by Week 24 — 34.1 percentage of subjects
Phase 2 N=22 Study of SB939 in Subjects With Myelofibrosis
Myeloproliferative Disorders
Primary: Participants With an Objective Response — 0; 0; 2 Participants
Phase 3 N=219 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial
Myelofibrosis
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 48 — 28.5; 0 Percentage of Participants — p=<0.0001
Phase 2 N=12 Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis
Myelofibrosis
Primary: Objective Response Rate (ORR) — 1; 9; 1 Participants
Phase 3 N=51 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis
Primary Myelofibrosis (MF)
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 50; 46; 12; 5 Participants
Phase 2 N=120 Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF
Primary Myelofibrosis (MF) · Post-Polycythemia Vera (PV) MF · Post-Essential Thrombocythemia (ET) MF
Primary: Percentage of Participants With at Least 35% Reduction in Spleen Volume From Baseline at Week 24 — 38 Participants — p=0.0007
Phase 2 N=66 Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)
MPN (Myeloproliferative Neoplasms)
Primary: Percent Change From Baseline in Spleen Volume at Week 24 by Final Titrated Dose — -11.6; -17.4; -22.4; -13.4 Percentage change from baseline — p=0.0250
Phase 3 N=309 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
MPN (Myeloproliferative Neoplasms)
Primary: Number of Participants Achieving ≥ 35% Reduction in Spleen Volume From Baseline to Week 24 — 65; 1 participants — p=<0.0001
Phase 2 N=41 Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients
Myelofibrosis
Primary: Percentage of Participants With at Least 1 Adverse Event From Baseline Through Week 16 — 78.0 Percentage of participants
Phase 2 N=22 CEP-701 for PH-negative Myelofibrosis
Leukemia · Myelofibrosis
Primary: Number of Participants With Objective Response — 0; 0; 6 Participants
Phase 2 N=50 LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase · Primary Myelofibrosis · Secondary Myelofibrosis
Primary: Number of Participants With a Response — 15 Participants
Phase 2 N=77 Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Primary Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis
Primary: Part 1 and Part 2: Number of Subjects With Adverse Events and Serious Adverse Event — 0; 0; 0; 0 Participants
Phase 4 N=48 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Primary Myelofibrosis (PMF) · Post Polycythaemia Myelofibrosis (PPV MF) · Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
Primary: Percentage of Participants With Treatment Success — 50 Percentage of participants
Phase 2 N=154 Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Myelofibrosis · Polycythemia Vera · Thrombocytosis
Primary: Number of Participants With Adverse Events (AEs) — 30; 35; 47; 5 participants
Phase 2 N=54 Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis
Myelofibrosis
Primary: Rate of Clinical Response as Defined by the Percentage of Participants With Reduction at Week 24 From Baseline in the Bone Marrow Fibrosis Score — 0; 16.7; 6.7; 13.3…
Phase 2 N=70 Pomalidomide for Myelofibrosis Patients
Polycythemia Vera · Thrombocythemia
Primary: Number of Participants With Best Overall Response — 0; 3; 6 Participants
Phase 2 N=88 A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia
Myelofibrosis With Myeloid Metaplasia · Myeloid Metaplasia · Myelofibrosis
Primary: Percentage of Participants With a Clinical Response Within the First 6 Cycles of Treatment — 55.0; 23.5; 21.1; 47.6 percentage of participants — p=0.092
Phase 2 N=31 Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
Myeloproliferative Diseases
Primary: Participants With Objective Response — 7 Participants
Phase 2 N=80 Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis
Primary Myelofibrosis · Secondary Myelofibrosis · Myeloid Malignancies
Primary: MF Participants: Percentage of Participants With Overall Response (OR) - (Clinical Improvement[CI] or Partial Remission[PR] or Complete Remission[CR]) Per International…
Phase 2 N=56 Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia
Anemia · Myelodysplastic/Myeloproliferative Neoplasm · Myelofibrosis
Primary: Anemia-response — 8; 6 Participants
Phase 1 N=69 Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
Myelofibrosis
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
Phase 2 N=66 Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
Myelofibrosis
Primary: The Primary Endpoint is Progression-free Survival. — 24; 11 participants
Phase 2 N=90 Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)
Myelofibrosis · Post-polycythemia Vera Myelofibrosis (PPV-MF) · Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants